PMV PHARMACEUTICALS $PMVP REPORTS 46% ORR IN OVARIAN CANCER TRIAL
Updated interim data from the PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy, per the company.
- Objective response rate: 46% among 76 ovarian cancer patients
- Median time to response: 1.3 months
- Median duration of response: 10.0 months
- Discontinuation rate due to adverse events: 5%
THANK Y'ALL FOR 2K 🎀
Thought I'd share the PMV I've nutted to the most 😵💫 So glad I made this 😅 ENJOY!!!!
LIKE & RETWEET if you'd be so kind 🫡
#babecock# #cum# #bbc# #goon# #tits#